Last updated: February 21, 2026
What Is the Product?
NDC 50228-0428 corresponds to Aspen's Carfilzomib Injection (brand name: Kyprolis). It is a proteasome inhibitor approved for treating multiple myeloma in relapsed or refractory cases. The drug is administered intravenously and primarily distributed through hospital and specialty clinics.
Market Overview
Market Size
The multiple myeloma market is steadily growing, driven by an aging population and expanding indications. The global multiple myeloma therapeutics market was valued at approximately $10 billion in 2022, growing at a compound annual growth rate (CAGR) of around 8% through 2027 [1].
Within this market, Carfilzomib holds a significant share owing to its efficacy in patients who have relapsed after prior treatments. The drug's market penetration depends on factors like approval breadth, formulary inclusion, and competition.
Competition Landscape
Key competitors include:
- Bortezomib (Velcade) from Takeda
- Ixazomib (Ninlaro) from Takeda
- Daratumumab (Darzalex) from Janssen
- Elotuzumab (Empliciti) from Bristol-Myers Squibb
The therapeutic competition influences pricing dynamics significantly, with newer agents often commanding higher prices due to improved efficacy or convenience.
Market Drivers
- Increased diagnosis rates
- Expanded labeling for earlier lines of therapy
- Growing reimbursement and insurance coverage
- Development of biosimilars and generics, affecting pricing
Market Challenges
- High treatment costs
- Adverse effect profiles necessitating case-by-case monitoring
- Competition from emerging therapies and biosimilars
Pricing Analysis
Current Wholesale Acquisition Cost (WAC)
As of 2023, the average WAC for a 60 mg vial of Carfilzomib is approximately $7,200. Treatment regimens typically involve multiple vials per cycle, with a standard course lasting six cycles or more.
Price Trends
- Introduction (2012): Launch price was around $6,500 per vial
- Recent updates (2021-2023): Increased by 10-15%, primarily due to inflation and value-based pricing strategies
- Negotiated net prices: Estimated at 20-30% lower than WAC, reflecting discounts and rebates
Cost-Effectiveness Considerations
The drug's high cost is mitigated by its efficacy in resistant cases. According to pharmacoeconomic analyses, Carfilzomib provides a survival benefit of approximately 4-8 months over placebo or less effective regimens [2].
Projected Market Growth and Pricing
Short-Term (Next 2 Years)
- Market growth rate: Approximately 6-8% annually
- Price projections: WAC likely to rise by 3-5% annually due to inflation and R&D costs
- Market penetration: Expected to increase with broader approval for front-line settings
Medium to Long-Term (3-5 Years)
- Price adjustments: Potential stabilization or slight decrease due to biosimilar entry
- Market volume: Anticipated to grow driven by improvements in patient outcomes
- Revenue forecasts: Industry projections suggest the U.S. market for Carfilzomib could reach $1.2 billion by 2026
Impact of Biosimilars
Biosimilar versions of Carfilzomib are entering the U.S. market, expected to reduce prices by 15-25%. This pressure will likely lower the average net price and expand access.
Regulatory and Reimbursement Outlook
- FDA approvals: Expanded indications for earlier lines of therapy in multiple myeloma
- CMS and private insurer policies: Increasing coverage with negotiated drug discounts, influencing net pricing
- Value-based pricing models: Emerging trends may cap prices based on patient outcomes
Summary Table of Pricing Data
| Metric |
2023 Estimate |
Notes |
| WAC per vial |
~$7,200 |
For 60 mg vial |
| Average Treatment Cost |
~$43,200 (6 vials per cycle) |
Based on standard regimen |
| Negotiated Net Price |
~$5,040 - $5,760 per vial |
Assuming 20-30% rebates |
| Market Value (2026) |
~$1.2 billion |
Estimated U.S. market size |
Key Takeaways
- NDC 50228-0428 (Carfilzomib) holds a substantial market share in multiple myeloma therapies.
- The global market is growing at 8% CAGR, with prices increasing moderately annually.
- Price projections for 2024-2026 indicate continued growth but face downward pressure from biosimilars.
- Reimbursement policies and regulatory approvals will influence net pricing and market access.
- Industry trend toward value-based agreements may further impact drug pricing strategies.
FAQs
Q1: What factors most influence the price of Carfilzomib?
A1: Regulatory approvals, competition, negotiation outcomes, and biosimilar entry significantly influence pricing.
Q2: How does biosimilar competition affect future pricing?
A2: Biosimilars are expected to lower prices by 15-25%, pressuring branded drug prices downward.
Q3: What is the typical treatment cost for Carfilzomib?
A3: Approximately $43,200 per treatment course, assuming six vials per cycle over six cycles, not including administration costs.
Q4: Are new indications likely to influence market size?
A4: Yes, expansion into earlier lines of therapy can increase market volume and sales.
Q5: How do reimbursement policies impact net pricing?
A5: Reimbursement negotiations and formulary inclusion determine the net price, often 20-30% lower than WAC.
References
[1] MarketWatch. (2022). Global Multiple Myeloma Market. Retrieved from https://www.marketwatch.com
[2] Smith, J., & Lee, K. (2021). Cost-effectiveness of Carfilzomib in relapsed multiple myeloma. Journal of Oncology Pharmacy Practice, 27(2), 234-245.
